Loading...
•
Jun 30
Tandem Diabetes Q2 2025 Earnings Report
Tandem Diabetes Care announced its second quarter 2025 financial results, reporting record sales in the U.S. and internationally, improved gross margin, and progress in product development and commercial initiatives.
Key Takeaways
Tandem Diabetes Care achieved record second quarter sales of $240.7 million, demonstrating year-over-year and sequential gross margin improvement. The company reported a GAAP net loss of $52.4 million and a non-GAAP net loss of $32.4 million, while increasing U.S. pump shipments and advancing key product and commercial initiatives.
Achieved record second quarter sales of $240.7 million, with strong performance both in the United States and internationally.
Demonstrated significant year-over-year and sequential gross margin improvement, reaching 52% GAAP gross margin.
Initiated an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S.
Received CE Mark for the Tandem Mobi insulin delivery system with Control-IQ+ technology, expanding its international market reach.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Segment
Tandem Diabetes Revenue by Geographic Location
Revenue by Segment
Pump Revenue
CapyFin.comSupplies and Other Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
Tandem Diabetes Care expects to achieve approximately $1.0 billion in worldwide sales for the full year 2025, with an estimated GAAP gross margin of 53% to 54%. The company has revised its Adjusted EBITDA margin guidance to approximately negative 5% of sales, reflecting an acquired in-process research and development charge.
Positive Outlook
- Anticipates reaching $1.0 billion in worldwide sales for the full year 2025, a significant milestone.
- Projects U.S. sales of approximately $700 million and international sales of approximately $300 million.
- Forecasts a GAAP gross margin of approximately 53% to 54% for the full year.
- Expects increased benefit from accelerated pharmacy channel initiatives.
- Anticipates greater contributions from international sales.
Challenges Ahead
- Revised Adjusted EBITDA margin guidance to approximately negative 5% of sales for the full year.
- Adjusted EBITDA margin includes a negative 8 percentage point impact for an acquired in-process research and development charge.
- International sales guidance reflects a $10 million headwind due to preparation for direct commercial operations in select countries.
- The company no longer includes an adjustment for IPR&D expense in its Non-GAAP results, impacting comparability.
- The narrowed guidance reflects insights gained in the first half of the year, including U.S. growth expectations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income